IL6 and hepatocellular carcinoma: Further researches on molecular mechanisms showed that activated STAT3 pathway by IL-6 upregulated CD47 expression in hepatocellular carcinoma cell lines, and the IL-6-STAT3 axis blockage reduced cancer cells' antiphagocytic ability via downregulation of CD47 expression [23].